In conclusion, although a clear relationship between radiation exposure from radiopharmaceutical therapy and CVD has not yet been established with scientific certainty, there is sufficient evidence in the literature to suggest that such a relationship may exist, and caution is warranted. We therefore advocate that the absorbed doses to the cardiovascular system after radiopharmaceutical therapies be closely monitored in order to obtain reliable data on the relationship between the absorbed doses and CVD. This in turn might help to better define the risk factor for CVD after the use of ionizing radiation.